MAKINDO MEDICINEClinical textbook for medical students and doctors
For education and revision only. Not for individual patient decisions or prescribing. Verify current NICE/BNF, MHRA safety advice and local clinical protocols before clinical use. Clinical safety and terms.
Chapter 289
MAKINDO MEDICINE · Biochemistry289

Biochemistry III: enzymes, vitamins, genetics and molecular mechanisms

Core principles: mechanisms are emphasised to explain clinical phenomena, physiological measurements and biochemical disease.

Enzyme kinetics and inhibition

ConceptDefinitionPractical meaning
Michaelis–Menten KmSubstrate concentration at half Vmax in simple modelLower Km often means higher apparent affinity but context matters
Competitive inhibitorRaises apparent Km, Vmax unchangedSurmountable by high substrate concentration
Non-competitive pure inhibitionLowers Vmax, Km unchangedCannot fully overcome by substrate
Uncompetitive inhibitionLowers Km and VmaxBinds enzyme-substrate complex
Allostery/cooperativitySigmoidal kinetics not simple MMHaemoglobin, regulatory enzymes

Water- and fat-soluble vitamins with clinical relevance

VitaminBiochemical roleDeficiency example
B1 thiaminePyruvate dehydrogenase, alpha-KGDH, transketolaseWernicke encephalopathy, beriberi
B2 riboflavinFMN/FAD redox cofactorsCheilosis, glossitis
B3 niacinNAD/NADP redoxPellagra (dermatitis, diarrhoea, dementia)
B5 pantothenateCoenzyme A synthesisRare; multisystem symptoms
B6 pyridoxineTransamination, neurotransmitter/haem synthesisNeuropathy, seizures, sideroblastic anaemia
B7 biotinCarboxylasesDermatitis, alopecia, metabolic acidosis
B9 folateOne-carbon transfer, thymidylate and purine synthesisMegaloblastic anaemia; fetal neural tube risk
B12 cobalaminMethionine synthase and methylmalonyl-CoA mutaseMegaloblastosis and neuropathy
C ascorbateCollagen prolyl/lysyl hydroxylation, antioxidantScurvy
A retinoidsVisual cycle and epithelial differentiationNight blindness
D calcitriolCalcium/phosphate absorption and bone mineral balanceOsteomalacia/rickets
E tocopherolLipid membrane antioxidantHaemolysis, neurological dysfunction
K phylloquinoneGamma-carboxylation coagulation proteinsBleeding, prolonged PT

Genetics, RNA and protein synthesis

  • DNA replication uses DNA polymerases with proofreading (except several organelle/specialised contexts); telomerase extends terminal repeats in selected cells.
  • Transcription by RNA polymerase II forms pre-mRNA, which undergoes capping, splicing and polyadenylation; alternative splicing increases protein diversity.
  • Ribosomes translate mRNA codons with aminoacyl-tRNAs; initiation, elongation and termination require specialised factors.
  • Autosomal dominant, recessive, X-linked and mitochondrial inheritance patterns each have characteristic pedigrees but penetrance, expressivity and de novo variation modify them.
  • Epigenetic DNA methylation/histone modification can alter transcription without DNA sequence change; genomic imprinting depends on parent of origin.

Cell signalling and tissue consequences

  • G-protein coupled receptors: Gs increases cAMP/PKA; Gi decreases cAMP; Gq activates PLC → IP3/DAG → cytosolic Ca2+ and PKC.
  • Insulin receptor tyrosine kinase recruits IRS/PI3K/AKT to promote GLUT4 translocation, glycogenesis and anabolic signalling.
  • p53 responds to DNA damage by cell-cycle arrest, senescence or apoptosis; Rb restrains E2F until appropriately phosphorylated.
  • Mitochondrial apoptosis is regulated by BCL2 family and cytochrome c/caspase activation; necroptosis and pyroptosis are distinct regulated death pathways.

Molecular diagnostics and clinical genetics

  • Enzyme kinetics: Competitive inhibition raises apparent Km without changing Vmax; non-competitive inhibition may lower Vmax. Enzyme assay interpretation requires attention to cofactors, substrate concentration and tissue source.
  • Variant interpretation: A variant of uncertain significance is not a molecular diagnosis. Classification integrates segregation, population frequency, functional data and phenotype; reclassification may occur as evidence changes.
  • DNA to protein: Replication proceeds 5′→3′ using polymerases and proofreading; transcription makes RNA and splice processing determines mature transcripts; translation converts codons to protein. Missense, nonsense, frameshift and splice variants can have different consequences.
  • Genomic testing: Sequence tests detect many single-nucleotide variants but may miss copy-number changes, repeat expansions and structural rearrangements unless specific methods are included. Mitochondrial heteroplasmy and tissue mosaicism add further sensitivity limits.

Vitamin cofactor clinical patterns

  • B1 and B6: Thiamine supports pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase; deficiency contributes to Wernicke encephalopathy, beriberi and lactic acidosis. Pyridoxal phosphate supports amino-acid metabolism and neurotransmitter synthesis; deficiency can cause neuropathy or seizures.
  • B9 and B12: Folate and cobalamin are essential for nucleotide synthesis; both can cause macrocytosis, but B12 deficiency also causes subacute combined degeneration and peripheral neuropathy. Serum markers and test limitations matter before treatment.
  • Fat-soluble vitamins: Vitamin A affects vision and epithelial differentiation, D calcium-phosphate homeostasis, E antioxidant protection and K gamma-carboxylation of coagulation proteins. Malabsorption, liver disease and medication exposures can alter status.

Further reading: OpenStax Anatomy & Physiology; USMLE Step 1 framework. Apply current specialist guidance for patient-care decisions. Educational expansion pending clinical editorial sign-off (2026).

End of chapter